Verastem Oncology gains Fast Track Designation for combination NSCLC treatment
January 19, 2024Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology
Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …
FDA clears DermaSensor’s AI detection device for skin cancer
January 18, 2024Medical Communications FDA, Oncology, skin cancer
DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …
Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment
January 18, 2024Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial
Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …
FDA clears Aruna Bio’s IND for AB126 to enter clinical trials
January 17, 2024Research and Development Aruna Bio, FDA, IND, Neurology, clinical trials
Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
January 17, 2024Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …
Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing
January 16, 2024Manufacturing and Production Pharmacy, Upperton Pharma Solutions, investment, sterile drug manufacturing
UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment to expand into a small-scale …
DelSiTech announces closing of €10m financing round for silica-based drug delivery platform
January 16, 2024Manufacturing and Production DelSiTech, Pharmacy, drug delivery, investment, manufacturing
DelSiTech has announced the successful completion of a €10m financing round, marking the largest single financing round in the company’s …
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
January 15, 2024Medical Communications FDA, Oncology, cervical cancer, keytruda
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Boan Biotech completes enrolment for phase 3 study of Denosumab
January 15, 2024Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab
Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
January 12, 2024Medical Communications COVID-19, Infections and infestations, NICE
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam
January 11, 2024Sales and Marketing Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration
Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in …
Isomorphic Labs to collaborate with Eli Lilly
January 11, 2024Research and Development AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery
Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
January 10, 2024Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
Fate Therapeutics initiates phase 1 trial for solid tumour treatment
January 9, 2024Research and Development Fate Therapeutics, Oncology, solid tumours
Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …
GSK to acquire Aiolos Bio for $1bn
January 9, 2024Business Services Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …
Consilient Health to launch Cytisine smoking cessation treatment in UK
January 8, 2024Sales and Marketing Cytisine, Smoking Cessation, consilient health, smoking cessation
Consilient Health has announced that it plans to launch Cytisine 1.5mg tablets in the UK on 22 January 2024. The …
Calypso Biotech to be acquired by Novartis for $250m
January 8, 2024Business Services Calypso Biotech, Immunology, Novartis, acquisition
Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …
Eli Lilly launches digital healthcare process
January 5, 2024Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity
Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …
Latest content
FibroFind appoints Lee Borthwick as CEO
